Xbira 250mg tablet (Abiraterone Acetate)- Anticancer drugs | Cipla | MHP
XBIRA
XIBRA 250MG |
DESCRIPTION
Xbira 250mg is belongs to anti neoplastic drugs which will work by Diminish the androgen production in the body. Androgen is a male hormone which balances the cancer cell in prostate glands.Normaly this tablet is taken by combination with prednisolone, a steroid which decreases the liability of side effects produced by Abiraterone.
Mechanism of Action
Androgens are regulates the production of tumors in prostate. X bira is an anti androgen drugs, which causes to eradicate the enzyme 17α-hydroxylase C 17, 20-lyase (CYP17), it is includes in androgen synthesis. Decrease the serum testosterone level. Diminished the tumor cell occurred.PHARMACOKINETICS
ABSORPTION
Time to median plasma concentration of tablet Xbira 250mg takes 12 hours.DISTRIBUTION
Maximum bound to the human plasma protein like albumin and alpha-1 acid glycoprotein.METABOLISM
The main two metabolites of Abiraterone in human plasma are Abiraterone sulphate and N-oxide Abiraterone sulphate.ELIMINATION
Terminal half life of tablet Xbira 250mg tablet is 12 ± 5 hours. The drug mainly excreted in 88% feces and 5% in urine.Brand : Xbira
Ingredients : Abiraterone acetate
Strength : 250mg
Manufactured : Cipla
Package : 120 TabletsDOSAGE MANAGEMENT
The usual dose of Xbira 250mg tablet is endorsed as 4 tablets orally once daily
The drug X bira given with 5mg prednisolone twice daily in empty stomach.
Xbira Tablets administrated on an empty stomach.
No food should be consumed for at least 2 hours before and at least 1 hour after the dose of XbiraTablets is taken.
Xbira should be swallowed whole with water.
Do not crush or chew the tablets.OVERDOSAGE
Xbira has no specific antitoxin, If overdose occurs stop the drug and provide general
supportive measures such as monitoring arrhythmias and cardiac failure and assess liver function.
Contact Us :
Mobile No : +91-9940472902
Email : millionhealthpharmaceuticals@gmail.com
Email : millionhealthpharmaceuticals@gmail.com
Comments
Post a Comment